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Abstract  
Background: There remains variability in both practice and evidence related to optimal initial empiric dosing strategies for vancomycin.  
Objective: Our primary objective was to describe the percentage of obese patients receiving vancomycin doses consistent with 
nomogram recommendations achieving targeted initial steady-state serum vancomycin concentrations. Secondary objectives were to 
describe the primary endpoint in subgroups based on patient weight and estimated creatinine clearance, to describe the rate of 
supratherapeutic vancomycin accumulation following an initial therapeutic trough concentration, and to describe the rate of 
vancomycin-related adverse events. 
Methods: This single-center, IRB-approved, retrospective cohort included adult patients ≥ 100 kilograms total body weight with a body 
mass index (BMI) >30 kilograms/m2 who received a stable nomogram-based vancomycin regimen and had at least one steady-state 
vancomycin trough concentration. Data collected included vancomycin regimens and concentrations, vancomycin indication, serum 
creatinine, and vancomycin-related adverse events. Patients were divided into two cohorts by goal trough concentration: 10-15 
mcg/mL and 15-20 mcg/mL.  
Results: Of 325 patients screened, 85 were included. Goal steady-state concentrations were reached in 42/85 (49.4%) of total patients. 
Conclusions: Achievement of initial steady-state vancomycin serum concentrations in the present study (approximately 50%) was 
consistent with the use of published vancomycin dosing nomograms.  
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INTRODUCTION 
More than one-third of adults in the United States are 
obese and consequently at a significantly increased risk for 
heart disease, stroke, and type 2 diabetes.1 In addition to 
these health implications, the physiologic changes from 
obesity also impact pharmacokinetic and 
pharmacodynamic properties of drugs. These changes can 
impact both efficacy and toxicity, especially in 
antimicrobials such as vancomcyin.2  
Vancomycin is a tricyclic glycopeptide antibiotic commonly 
used as therapy for infections caused by Gram-positive 
organisms, most notably methicillin-resistant 
Staphylococcus aureus (MRSA).3 Published adult dosing 
recommendations for vancomycin in the general 
population are 15 to 20 mg/kg per dose every 8 to 24 hours 
(based upon total body weight [TBW] and estimated renal 
function).4 However, such recommendations may be 
inadequate in obese patients due to increases in 
vancomycin clearance and volume of distribution.5 In 
addition, when applied to obese patients, the large single 
doses resulting from such weight-based recommendations 
increase the risk of dose-related toxicities.5  
Variability in both practice and lack of evidence related to 
optimal initial dosing strategies for vancomycin exist.5 For 
example, dosing based on TBW achieves target steady-
state trough concentrations more frequently then when 
based on ideal body weight (IBW).2 In contrast, one study5 
demonstrated that use of adjusted body weight (ABW) 
provided the best predictor to serum concentrations, and 
another6 recommended using 45 to 65 mg/kg/day based on 
IBW.5-6 In addition to weight-based dosing, published 
dosing nomograms have also been extensively evaluated.7-9 
Their efficacy in achieving initial goal trough concentrations 
(10-20 mcg/mL) has been shown to range from 40-60% on 
the initial regimen, but the majority excluded patients 
weighing more than 120 kg or limited the maximum single 
dose to 2 gms.
7-9
 Studies analyzing appropriate vancomycin 
dosing and monitoring in obese patients have reported 
variable success rates. In one, approximately 60% of initial 
vancomycin steady-state concentrations were 
subtherapeutic (<10 mcg/mL), leading to increased risk of 
resistance and treatment failure.8 Another concluded that 
obese patients most often reached target trough 
Original Research 
Evaluation of a vancomycin dosing nomogram in obese 
patients weighing at least 100 kilograms 
Riley D. BOWERS , April A. COOPER , Catherine L. WENTE , Dustin T. WILSON ,  
Steven W. JOHNSON , Richard H. DREW . 
Received (first version):  1-Feb-2018   Accepted: 4-Jul-2018  Published online: 13-Aug-2018 
 
Riley D. BOWERS. PharmD, BCPS. Department of Pharmacy 
Practice, College of Pharmacy & Health Sciences, Campbell 
University. Buies Creek, NC; & Cape Fear Valley Medical Center. 
Fayetteville, NC (United States). bowers@campbell.edu 
April A. COOPER. PharmD. Department of Pharmacy Practice, 
College of Pharmacy & Health Sciences, Campbell University. Buies 
Creek, NC; & Duke Regional Hospital. Durham, NC (United States). 
april.cooper@duke.edu 
Catherine Lewis WENTE. PharmD, CACP, BCPS. Department of 
Pharmacy Practice, College of Pharmacy & Health Sciences, 
Campbell University. Buies Creek, NC; & Duke Regional Hospital. 
Durham, NC (United States). Catherine.d.lewis@duke.edu 
Dustin T. WILSON. PharmD, BCPS. Department of Pharmacy 
Practice, College of Pharmacy & Health Sciences, Campbell 
University. Buies Creek, NC; & Duke University Hospital. Durham, 
NC (United States). wilsond@campbell.edu 
Steven W. JOHNSON. PharmD, BCPS, CCP, AAHIVP. Department 
of Pharmacy Practice, College of Pharmacy & Health Sciences, 
Campbell University. Buies Creek, NC; & Novant Health - Forsyth 
Medical Center. Winston-Salem, NC (United States). 
johnsonsw@campbell.edu 
Richard H. DREW. PharmD, MS, FCCP. Department of Pharmacy 
Practice, College of Pharmacy & Health Sciences, Campbell 
University. Buies Creek, NC; & Duke University School of Medicine. 
Durham, NC (United States). Richard.drew@duke.edu 
 A
rt
ic
le
 d
is
tr
ib
u
te
d
 u
n
d
er
 t
h
e 
C
re
at
iv
e 
C
o
m
m
o
n
s 
A
tt
ri
b
u
ti
o
n
-N
o
n
C
o
m
m
er
ci
al
-N
o
D
er
iv
s 
3
.0
 U
n
p
o
rt
ed
 (
C
C
 B
Y-
N
C
-N
D
 3
.0
) 
lic
en
se
 
Bowers RD, Cooper AA, Wente CL, Wilson DT, Johnson SW, Drew RH. Evaluation of a vancomycin dosing nomogram in obese 
patients weighing at least 100 kilograms. Pharmacy Practice 2018 Jul-Sep;16(3):1204.  
https://doi.org/10.18549/PharmPract.2018.03.1204 
 
www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X) 2 
concentrations when given 20-30 mg/kg/day based on 
TBW.9 
There has yet to be a consensus or guideline 
recommendations for dosing and monitoring in obese 
patients. At Duke University Hospital, a validated empiric 
dosing nomogram for patients weighing 50-100 kg has been 
in place since 2010. In order to fulfill an increasing and 
unmet need, an empiric vancomycin dosing nomogram was 
developed at Duke Regional Hospital (DRH) in 2016 
targeting patients weighing 100 to 160 kg (see Appendix). 
While we hypothesized this nomogram would provide 
appropriate initial vancomycin dosing guidelines in this 
population, it had not been previously evaluated. The 
purpose of our study was to evaluate this newly-
implemented vancomycin dosing nomogram in achieving 
goal steady-state trough concentrations for obese adult 
patients.  
 
METHODS 
The primary objective of this single-center, retrospective 
cohort study was to describe the percentage of obese 
patients receiving initial vancomycin doses consistent with 
nomogram recommendations achieving targeted initial 
steady-state serum vancomycin concentrations. The 
secondary objectives were to describe the primary 
endpoint in subgroups based on patient weight and 
estimated creatinine clearance (CrCl). We also sought to 
describe the percentage of patients maintaining a target 
steady-state trough concentration, on a consistent 
regimen, for one subsequent level following an initial target 
steady-state trough concentration to assess the rate of 
accumulation. Lastly, patients were evaluated for 
vancomycin-related adverse effects, including new-onset 
kidney injury and Red Man syndrome.  
This single-center, retrospective cohort study was approved 
by the Duke University Health System Institutional Review 
Board and conducted at DRH, a 369-bed community 
hospital in Durham, NC. Patients >18 years-old, admitted to 
a general medicine or surgery unit from December 1, 2015 
to February 1, 2017 were included. Subjects who weighed 
>100 kg and had a BMI of >30 kg/m2 who received at least 
2 scheduled vancomycin doses following the appropriate 
loading dose (per nomogram recommendations) were 
included if at least one steady-state trough vancomycin 
concentration (defined as following at least the third dose 
of the regimen and drawn within 2 hours of the next 
sequential dose) was measured. Patients were excluded for 
any of the following: renal dysfunction (defined as an 
estimated CrCl <10 mL/min), unstable renal function 
(defined as a change in serum creatinine (SCr) of 0.5 mg/dL 
or 50% reduction in estimated CrCl between initial dose 
and time of subsequent trough measurement), moderate 
to severe liver dysfunction at baseline (defined as aspartate 
aminotransferase or alanine aminotransferase levels >two 
times the upper limit of normal (ULN), or a total bilirubin 
level >two times the ULN), ascites, burns (>20% total body 
surface area), within 30 days of solid organ or 
hematopoietic stem cell transplantation, had cystic fibrosis, 
were patients in the critical care unit, or were pregnant.  
Patients were identified utilizing the Duke Enterprise Data 
Unified Content Explorer (DEDUCE). Separate admissions 
for the same patient were counted as individual cases. Data 
were collected using a Microsoft Access database and entry 
form. Patient demographics collected included gender, age, 
weight, height, BMI, and the presence of chronic kidney 
disease (CKD). Other data collected included vancomycin 
indication, vancomycin dosing regimens, and vancomycin 
serum trough concentrations, dates, and collection times. 
SCr and estimated CrCl at time of vancomycin initiation and 
trough concentration of maintenance regimen utilizing a 
modified Cockroft-Gault equation (removing weight and 72 
from numerator and denominator, respectively).10 Of note, 
in patients >70 years old, a SCr below 1 mg/dL was rounded 
to 1 mg/dL to calculate CrCl. For initial loading doses, 
patients received 25 mg/kg TBW unless they had impaired 
renal function indicated by new-onset kidney injury or CKD 
Stage IV or worse. In this case, patients were loaded with 
20 mg/kg TBW. However, we incorporated our institution’s 
policy of vancomycin dose capping at 2500 mg. For patients 
with therapeutic serum trough concentrations that were 
continued on the same regimen, SCr was collected again at 
the time of the next trough concentration. Lastly, presence 
of Red Man syndrome and new-onset kidney injury at the 
time of concentration collection (defined as an increase in 
SCr by 0.3 mg/dL or more within 48 hours, or an increase in 
SCr to 1.5 times baseline or more within the last 7 days, or 
urine output less than 0.5 mL/kg/h for 6 hours) was 
collected.11 The institutional nomogram was developed 
with the above in mind, utilizing traditional vancomycin 
pharmacokinetic calculations including the Matzke 
equation for the elimination rate constant. For patients 
receiving multiple courses of vancomycin during a single 
admission, only the first course was included in the study.12  
Data Analysis 
The primary endpoint (initial steady-state serum 
vancomycin concentration within the indication-specific 
target range) and patient demographics were characterized 
using descriptive statistics. For the secondary objectives, 
the endpoints utilized were percentage of therapeutic 
trough concentrations in the pre-specified cohorts, 
percentage of patients experiencing vancomycin 
accumulation to a supratherapeutic level following an 
initial therapeutic concentration, and percentage of 
patients experiencing a vancomycin-related adverse event 
such as new-onset kidney injury. Patients were cohorted by 
CrCl (10-39 mL/min, 40-69 mL/min, 70-99 mL/min, and 
100+ mL/min) and weight (100-119 kg, 120-139 kg, 140-159 
kg, and 160+ kg).  
 
RESULTS  
Of 325 patients weighing over 100 kg and on vancomycin 
identified and screened, 85 (26.2%) met inclusion criteria. 
Patients were excluded for the following: doses were not 
consistent with nomogram recommendations (n=168), no 
trough concentration level (n=36), critical care unit status 
(n=28), BMI <30 kg/m2 (5), and weight <100 kg at time of 
vancomycin initiation (3). The study population was 
predominantly male with an average age of 60 years. 
Remaining subject demographics are summarized in Table 
1. All subjects had an estimated CrCl > 30 mL/min and the 
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mean CrCl was 81.3 mL/min. The majority of patients were 
in the 15-20 mcg/mL goal trough cohort and were receiving 
therapy for complicated skin and skin structure infections 
(SSTI). 
Goal steady-state trough concentrations were reached in 
42 patients (49.4%) with 27 (47.4%) in the 15-20 mcg/mL 
cohort and 15 (53.6%) in the 10-15 mcg/mL cohort. In the 
total population, 24.7% had subtherapeutic levels at steady 
state and 25.9% had supratherapeutic levels. There was 
also a similar distribution of subtherapeutic levels and 
supratherapeutic levels in each goal trough subgroup 
(Figure 1). Trough levels ranged from 6.1-30.9 mcg/mL. 
When this data was combined, 58 patients (68.2%) had 
levels that fell in the 10-20 mcg/mL range.  
When divided into pre-specified subgroups based on goal 
trough concentrations, weight, and estimated CrCl (Table 
2), the majority of patients fell into the 100-119 kg groups 
(n= 47, 55%). There were a limited number of patients >140 
kg (n=13, 15%), and only 28 patients had an estimated CrCl 
<70 mL/min. 69% of the pre-specified subgroups containing 
at least one patient in the 15-20 mcg/mL goal cohort and 
67% of the subgroups in the 10-15 mcg/mL cohort had 
mean trough concentrations at goal, respectively (Table 2). 
Notably, 16/21 (76%) of total patients with subtherapeutic 
trough concentrations had an estimated CrCl >70 mL/min. 
However, there were more patients in these subgroups and 
the majority still achieved goal trough concentrations 
(n=30, 52.6%). There was a noticeably higher rate of 
Table 1. Baseline demographic characteristics of included subjects (by cohort) 
 
Parameter 
Cohort 
10-15 mcg/mL 
(n=28) 
15-20 mcg/mL 
(n=57) 
All patients 
(n=85) 
Age, yr  56.1 (11.8) 57.5 (15.2) 56.9 (13.0) 
Gender, n (Male:Female) 15:13 37:20 52:33 
Weight, kg  133.2 (35.6) 122.0 (17.6) 125.1 (25.3) 
BMI, kg/m
2 a
 44.8 (12.7) 39.5 (7.3) 40.9 (9.5) 
CrCl
b
, mL/min  98.8 (22.1) 72.7 (24.6) 81.3 (26.7) 
Indications, n(%)    
SSTI
c
 26 (92.9) 17 (29.8) 43 (50.1) 
Osteomyelitis 0 16 (28.1) 16 (18.8) 
Sepsis 0 11 (19.3) 11 (12.9) 
Pneumonia  0 6 (10.5) 6 (7.1) 
Bacteremia  1 (3.6) 4 (7.0) 5 (5.9) 
Intra-abdominal 0 3 (5.3) 3 (3.5) 
Other 1 (3.6) 0 1 (1.2) 
Vancomcyin regimen    
1.5g Q12H 11 11 22 (25.9) 
1.75g Q12H 5 10 15 (17.6) 
2g Q12H 4 8 12 (14.1) 
1.75g Q18H 0 8 8 (9.4) 
1.25g Q8H 0 6 6 (7.1) 
Other 8 14 22 (25.9) 
Baseline renal disease    
CKD
d
 Stage III-V 1 (3.6) 9 (15.8) 10 (11.8) 
a. Body Mass Index b. Creatinine clearance in normalized Cockroft-Gault c. skin and soft tissue infections d. 
Chronic Kidney Disease 
Figure 1. Number achieving trough concentrations based on target trough concentration goal. 
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patients reaching initial supratherapeutic trough 
concentrations in the CrCl <70 mL/min subgroups 
compared to those with a CrCl >70 mL/min (35.7% vs. 
19.3%).  
Very few patients were continued on the same vancomycin 
regimen following the achievement of a target trough 
concentration long enough to check a second 
concentration (n=11, 26.2%). Of these 11 patients, 5 
experienced accumulation to a supratherapeutic trough 
concentration on the subsequent level, with a mean (SD) 
time to next level of 2.9 (SD=1.2) days. However, 3 (60%) of 
these patients developed new-onset kidney injury between 
the first and second concentration drawn. 
No patients had to have vancomycin discontinued due to 
adverse events. Five patients experienced new-onset 
kidney injury during treatment and one patient was 
reported to have Red Man syndrome which was noted to 
improve when the infusion was administered at a slower 
rate. No other drug-related adverse effects were reported. 
 
DISCUSSION 
The results of our study found that our nomogram achieved 
target trough concentrations nearly 50% of the time. Prior 
attempts to utilize nomograms to provide initial dosing 
recommendations for vancomycin in obese patients have 
been met with variable success. One protocol employed a 
20 mg/kg loading dose followed by 10 mg/kg/dose (based 
on TBW) every 12-24 hours in morbidly obese adults (BMI 
>40).8 This dose was chosen based on previous findings 
that demonstrated a high rate of supratherapeutic 
concentrations with higher doses.8 With this decreased 
dose, initial goal trough concentrations were achieved in 
35.4% of patients, while subtherapeutic troughs occurred in 
56.3% and supratherapeutic troughs in only 8.3% of 
patients.8 Another recent retrospective study concluded 
that obese (BMI 30-40) and morbidly obese (BMI >40) 
patients most often reached target trough concentrations 
when given 20-30 mg/kg/day based on TBW.9 However, 
this study had limitations which included a high rate of 
subtherapeutic trough concentrations (48%) and no loading 
doses were given.9 
Compared to the aformentioned studies and another by 
Morrill et al, which utilized a similar dosing strategy and 
yielded 48% subtherapeutic initial trough levels, our study 
had a more even distribution of non-therapeutic trough 
concentrations.7-9 Approximately 25% of patients had 
subtherapeutic trough levels with no level being lower than 
6 mcg/mL, while another 25% of patients had 
supratherapeutic levels with only one level being greater 
than 30 mcg/mL (30.9). While we had a slightly higher rate 
of new-onset kidney injury during therapy compared to the 
previous trials, all patients experiencing kidney injury were 
on concomitant nephrotoxic medications including 
piperacillin-tazobactam, thiazide diuretics, and intravenous 
acyclovir.8,9,13  
The results of this study fall within the range of results in 
previous studies evaluating vancomycin dosing 
nomograms, achieving goal steady-state trough 
concentrations nearly 50% of the time.7,14-16 Unlike the 
majority of previous studies analyzing vancomycin 
nomograms, this study only included obese patients 
weighing at least 100 kg with no maximum weight.4-7,14-16 
When looking at the limited previous literature on 
vancomycin dosing in obese patients, our nomogram 
appears to be safe and similarly effective. Notable studies 
analyzing vancomycin dosing in obese patients have utilized 
protocols or nomograms that have based dosing on 
simplified mg/kg calculations paired with estimated renal 
function for determining frequency.8,9,13 Our nomogram 
was developed utilizing traditional pharmacokinetic 
calculations for each subgroup using TBW for volume of 
distribution calculations and normalized CrCl which 
ultimately leads to a lower estimation of drug clearance in 
these patients. Utilizing this method of dosing, we 
predicted that our patients would receive large enough 
doses without experiencing toxic levels as a result of too 
frequent dosing.  
This was also the first study to our knowledge to collect 
data on vancomycin accumulation in the real-world obese 
patient population. While our data is limited to 11 patients 
who were continued on their original therapeutic regimen 
long enough to receive a second trough level, it does reveal 
a concern for drug accumulation in this population. Nearly 
half (45%) of these patients experienced a subsequent 
supratherapeutic level following an initial therapeutic 
trough concentration and no change in dosing regimen. It is 
important to note that 3 of these patients had significant 
increases in SCr levels near the time of the follow-up level. 
Further studies are needed in this area to assess 
vancomycin adjustments in these patients to avoid 
potentially toxic accumulation.  
Our study was not without limitations. Though our 
nomogram was designed using common calculations 
utilized in clinical practice, there are potential limitations 
with the pharmacokinetics of using the standard Vd, 
Matzke equation, and SCr rounding in the obese 
population.12 However, there is no current consensus on 
the best method. AUC-based monitoring has also shown 
promising data, but until more implementable evidence 
Table 2. Subgroup analysis – average trough concentration (SD), mcg/mL 
10-15 mcg/mL goal 100-119 kg 120-139 kg 140-159 kg > 160 kg 
10-39 mL/min N/A N/A N/A N/A 
40-69 mL/min 17.0 (3.6) 22.8 (0)* N/A N/A 
70-99 mL/min 14.4 (5.7) 11.5 (0)* N/A 13.8 (1.6) 
> 100 mL/min  10.7 (2.9) 9.8 (3.6) 14.5 (0)* 14.8 (3.8) 
15-20 mcg/mL goal 100-119 kg 120-139 kg 140-159 kg > 160 kg 
10-39 mL/min 18.6 (2.4) 16.1 (0)* N/A N/A 
40-69 mL/min 17.2 (4.8) 18.8 (4.3) 19.9 (0)* 14.2 + 6.1* 
70-99 mL/min 16.9 (5.6) 18.7 (4.0) 11.5 (0)* N/A 
> 100 mL/min  12.6 (3.0) 23.2 (2.1)* 17.8 (0)* 15.4 (0)* 
*<2 patients represented in the subgroup 
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exists, many institutions will continue traditional 
vancomycin dosing.17 With no active or historical 
comparator, we were only able to report descriptive 
statistics limiting ability to show any association with 
patient specific factors and vancomycin concentrations. We 
were also limited to a small sample size. Although over 300 
patients were screened for inclusion, pharmacists were not 
required to utilize the nomogram during the evaluation 
period which led to many exclusions. We also excluded 
patients in the critical care unit per the institution’s 
pharmacokinetic policy which limits extrapolation to these 
patients. This limited sample size and utilization also 
inhibited our ability to truly evaluate the effectiveness of 
our nomogram in patients with poor CrCl and those 
weighing over 140 kg. Lastly, we did not evaluate clinical 
outcomes of the patients. 
 
CONCLUSIONS 
Overall achievement of initial steady-state vancomycin 
serum concentrations in our study of obese patients 
(approximately 50%) was consistent with the use of 
published vancomycin dosing nomograms. Notably, our 
study had an even distribution of non-therapeutic trough 
concentrations (25% subtherapeutic and 25% 
supratherapeutic). Our study also added evidence for the 
risk vancomycin accumulation in continued dosing in this 
patient population. Future plans should include identifying 
patient-specific factors associated with non-therapeutic 
trough levels in the obese patient population and 
developing accurate pharmacokinetic models for this 
population.  
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